Manager TitleAgeSince
Chief Operating Officer - -
Corporate Officer/Principal - -
Comptroller/Controller/Auditor - -
Date Insider Type Main position Quantity % Market Cap. Importance
6/6/23 A Other

Chief Executive Officer

61,085 0.2341%
12/28/22 A
Deerfield Management Co. LP
SellCompany 336,235 1.2945%
12/22/22 A
Deerfield Management Co. LP
SellCompany 73,384 0.2825%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%+869.23% - - 3.29M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.23%+4.72%+52.88%+164.14% 43.63B
Weighted average by Cap. +0.01%+3.64%+49.57%+162.47%
Logo Oncorus, Inc.
Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
Employees
64
  1. Stock Market
  2. Stocks
  3. ONCR Stock